LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,705
تعداد دریافت فایل اصل مقاله11,291,488
Tavakoli, Ali, Lotfi, Farhad, Lotfi, Mehrzad, Bayati, Mohsen, Seif, Mozhgan, Salesi, Mahmood, Emadi, Mehrnoosh, Keshavarz, Khosro, Delavari, Sajad. (1402). COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study. سامانه مدیریت نشریات علمی, 48(3), 302-312. doi: 10.30476/ijms.2022.94615.2598
Ali Tavakoli; Farhad Lotfi; Mehrzad Lotfi; Mohsen Bayati; Mozhgan Seif; Mahmood Salesi; Mehrnoosh Emadi; Khosro Keshavarz; Sajad Delavari. "COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study". سامانه مدیریت نشریات علمی, 48, 3, 1402, 302-312. doi: 10.30476/ijms.2022.94615.2598
Tavakoli, Ali, Lotfi, Farhad, Lotfi, Mehrzad, Bayati, Mohsen, Seif, Mozhgan, Salesi, Mahmood, Emadi, Mehrnoosh, Keshavarz, Khosro, Delavari, Sajad. (1402). 'COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study', سامانه مدیریت نشریات علمی, 48(3), pp. 302-312. doi: 10.30476/ijms.2022.94615.2598
Tavakoli, Ali, Lotfi, Farhad, Lotfi, Mehrzad, Bayati, Mohsen, Seif, Mozhgan, Salesi, Mahmood, Emadi, Mehrnoosh, Keshavarz, Khosro, Delavari, Sajad. COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study. سامانه مدیریت نشریات علمی, 1402; 48(3): 302-312. doi: 10.30476/ijms.2022.94615.2598

COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study

Iranian Journal of Medical Sciences
مقاله 8، دوره 48، شماره 3، مرداد 2023، صفحه 302-312    اصل مقاله (381.76 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.94615.2598
نویسندگان
Ali Tavakoli1؛ Farhad Lotfi2، 3؛ Mehrzad Lotfi4؛ Mohsen Bayati2؛ Mozhgan Seif5؛ Mahmood Salesi6؛ Mehrnoosh Emadi7؛ Khosro Keshavarz* 2، 3؛ Sajad Delavari2
1Research Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Health Human Resources Research Center, Department of Health Economics, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
3Emergency Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4Medical Imaging Research Center, Department of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran
6Chemical Injuries Research Ccenter, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
7Student Research Committee, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Reinfection with Coronavirus Diseases 2019 (COVID-19) has raised remarkable public health concerns globally. Therefore, the present retrospective cohort study intended to investigate COVID-19 reinfection in registered patients of Fars province in Iran from February 2020 to 
April 2021.
Methods: The patients’ data, including the COVID-19 infection, symptoms, comorbidities, and demographics, were collected using the Health Information Systems (HISs). The patients were divided into three groups in terms of the duration between the initial infection and reinfection, including 28-44, 45-89, and more than 90 days. Following the univariate analysis, logistic regression was used to investigate the factors effective on COVID-19 reinfection. 
Results: A total of 213768 patients had a positive Polymerase Chain Reaction (PCR) test. The reinfection rate was 0.97% (2079 patients). Of these re-infected individuals, 14.9%, 18.5%, and 66.6% had their second positive test 28-45, 45-89, and ≥90 days later, respectively. The mean duration between the initial infection and reinfection was 130.56 days (29-370 days). The chance of reinfection was significantly higher in the youths (Odds Ratio (OR)=2.055; P<0.001), men (OR=1.283; P<0.001), urban population (OR=1.313; P<0.001), and healthcare providers (OR=4.453; P<0.001). The patients with chronic pulmonary diseases, chronic kidney diseases, and malignancy were 1.421 (P=0.036), 2.239 (P<0.001), and 3.437 (P<0.001) times, respectively, more likely prone to reinfection. 
Conclusion: The results of this study showed that there is a higher risk of reinfection in several vulnerable groups including healthcare providers, young individuals, residents of urban areas, men, and individuals with underlying diseases. 
کلیدواژه‌ها
Coronavirus؛ Incidence؛ Reinfection؛ COVID-19؛ Communicable diseases
سایر فایل های مرتبط با مقاله
مراجع
  1. Worldometer [Internet]. Coronavirus Statistics 2022. [Update 03 December 2022]. Available from: https://www.worldometers.info/coronavirus/
  2. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395:1225-8. doi: 10.1016/S0140-6736(20)30627-9. PubMed PMID: 32178769; PubMed Central PMCID: PMCPMC7102589.
  3. Zangrillo A, Beretta L, Silvani P, Colombo S, Scandroglio AM, Dell’Acqua A, et al. Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. Crit Care Resusc. 2020;22:91-4. PubMed PMID: 32227819.
  4. Lafaie L, Celarier T, Goethals L, Pozzetto B, Grange S, Ojardias E, et al. Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases. J Am Geriatr Soc. 2020;68:2179-83. doi: 10.1111/jgs.16728. PubMed PMID: 32638347; PubMed Central PMCID: PMCPMC7361461.
  5. Kim YI, Kim SM, Park SJ, Kim EH, Yu KM, Chang JH, et al. Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerg Microbes Infect. 2021;10:152-60. doi: 10.1080/22221751.2021.1872352. PubMed PMID: 33407005; PubMed Central PMCID: PMCPMC7832474.
  6. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21:52-8. doi: 10.1016/S1473-3099(20)30764-7. PubMed PMID: 33058797; PubMed Central PMCID: PMCPMC7550103.
  7. Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. Clin Infect Dis. 2021;73:e4223-e8. doi: 10.1093/cid/ciaa1866. PubMed PMID: 33338197; PubMed Central PMCID: PMCPMC7799323.
  8. de la Vega R, Ruiz-Barquin R, Boros S, Szabo A. Could attitudes toward COVID-19 in Spain render men more vulnerable than women? Glob Public Health. 2020;15:1278-91. doi: 10.1080/17441692.2020.1791212. PubMed PMID: 32623959.
  9. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595-606. doi: 10.1016/S0140-6736(20)32137-1. PubMed PMID: 33065034; PubMed Central PMCID: PMCPMC7553736.
  10. Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2021;59. doi: 10.1128/JCM.02769-20. PubMed PMID: 33361342; PubMed Central PMCID: PMCPMC8092746.
  11. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, et al. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. MedRxiv. 2021. doi: 10.1101/2021.01.15.21249731.
  12. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397:1204-12. doi: 10.1016/S0140-6736(21)00575-4. PubMed PMID: 33743221; PubMed Central PMCID: PMCPMC7969130.
  13. Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51:e13520. doi: 10.1111/eci.13520. PubMed PMID: 33583018; PubMed Central PMCID: PMCPMC7988582.
  14. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2021;384:533-40. doi: 10.1056/NEJMoa2034545. PubMed PMID: 33369366; PubMed Central PMCID: PMCPMC7781098.
  15. Tuan J, Spichler-Moffarah A, Ogbuagu O. A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? BMJ Case Rep. 2021;14. doi: 10.1136/bcr-2020-240531. PubMed PMID: 33542020; PubMed Central PMCID: PMCPMC8098910.
  16. Organization WH [Internet]. Ageing and Health. [Cited 25 February 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
  17. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting the criteria for SARS-CoV-2 reinfection - six possible cases. J Infect. 2021;82:282-327. doi: 10.1016/j.jinf.2020.08.011. PubMed PMID: 32800801; PubMed Central PMCID: PMCPMC7422822.
  18. Zare F, Teimouri M, Khosravi A, Rohani-Rasaf M, Chaman R, Hosseinzadeh A, et al. COVID-19 re-infection in Shahroud, Iran: a follow-up study. Epidemiol Infect. 2021;149:e159. doi: 10.1017/S095026882100087X. PubMed PMID: 33866988; PubMed Central PMCID: PMCPMC8267335.
  19. Agresti A. Categorical data analysis. New Jersey: John Wiley and Sons; 2003. doi: 10.1002/0471249688.
  20. Dietz K, Gail M, Krickeberg K, Samet J, Tsiatis A. StatisticsStatistics for Biology and Health. Survival Analysis, Edition Springer. 2002;7.
  21. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis. 2020;20:1401-8. doi: 10.1016/S1473-3099(20)30589-2. PubMed PMID: 32758438; PubMed Central PMCID: PMCPMC7398038.
  22. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:331-40. doi: 10.1016/j.cmi.2020.10.020. PubMed PMID: 33228974; PubMed Central PMCID: PMCPMC7584920.
  23. Perez G, Banon T, Gazit S, Moshe SB, Wortsman J, Grupel D, et al. A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. MedRxiv. 2021. doi: 10.1101/2021.03.06.21253051.
  24. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020;10:20692. doi: 10.1038/s41598-020-77739-y. PubMed PMID: 33244060; PubMed Central PMCID: PMCPMC7691365.
  25. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71:2027-34. doi: 10.1093/cid/ciaa344. PubMed PMID: 32221519; PubMed Central PMCID: PMCPMC7184337.
  26. Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect. 2021;82:399-406. doi: 10.1016/j.jinf.2021.01.020. PubMed PMID: 33589297; PubMed Central PMCID: PMCPMC7880834.
  27. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Compr Clin Med. 2020;2:874-6. doi: 10.1007/s42399-020-00341-w. PubMed PMID: 32838138; PubMed Central PMCID: PMCPMC7271824.
  28. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. doi: 10.1016/j.ijid.2020.03.017. PubMed PMID: 32173574; PubMed Central PMCID: PMCPMC7194638.
  29. Hall V, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. Medrxiv. 2021. doi: 10.2139/ssrn.3768524.
  30. Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, et al. Secondary Infections in Hospitalized COVID-19 Patients: Indian Experience. Infect Drug Resist. 2021;14:1893-903. doi: 10.2147/IDR.S299774. PubMed PMID: 34079300; PubMed Central PMCID: PMCPMC8164345.
  31. Krishna VN, Ahmad M, Overton ET, Jain G. Recurrent COVID-19 in Hemodialysis: A Case Report of 2 Possible Reinfections. Kidney Med. 2021;3:447-50. doi: 10.1016/j.xkme.2021.02.004. PubMed PMID: 33748738; PubMed Central PMCID: PMCPMC7968169.
  32. Xiao Y, Rouzine IM, Bianco S, Acevedo A, Goldstein EF, Farkov M, et al. RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence. Cell Host Microbe. 2016;19:493-503. doi: 10.1016/j.chom.2016.03.009. PubMed PMID: 27078068; PubMed Central PMCID: PMCPMC4840895.
  33. Kapoor R, Nair RK, Nayan N, Bhalla S, Singh J. Reinfection or Reactivation of Coronavirus-19 in Patients with Hematologic Malignancies: Case Report Series. SN Compr Clin Med. 2021;3:670-4. doi: 10.1007/s42399-021-00790-x. PubMed PMID: 33585797; PubMed Central PMCID: PMCPMC7873512.
  34. Bellesso M, Bruniera FR, Trunkel AT, Nicodemo IP. Second COVID-19 infection in a patient with multiple myeloma in Brazil - reinfection or reactivation? Hematol Transfus Cell Ther. 2021;43:109-11. doi: 10.1016/j.htct.2020.12.002. PubMed PMID: 33423984; PubMed Central PMCID: PMCPMC7837121.
  35. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120-34. doi: 10.1016/j.jhin.2020.11.008. PubMed PMID: 33212126; PubMed Central PMCID: PMCPMC7668234.
  36. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi: 10.1016/j.rmed.2020.105941. PubMed PMID: 32421537; PubMed Central PMCID: PMCPMC7154502.
  37. Pan L, Wang R, Yu N, Hu C, Yan J, Zhang X, et al. Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. Eur J Clin Microbiol Infect Dis. 2021;40:1245-52. doi: 10.1007/s10096-020-04151-9. PubMed PMID: 33447913; PubMed Central PMCID: PMCPMC7808928.
  38. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, et al. Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain. Clin Infect Dis. 2021;73:354-6. doi: 10.1093/cid/ciaa1330. PubMed PMID: 32887979; PubMed Central PMCID: PMCPMC7499557.
  39. Fageeh H, Alshehri A, Fageeh H, Bizzoca ME, Lo Muzio L, Quadri MFA. Re-infection of SARS-CoV-2: A case in a young dental healthcare worker. J Infect Public Health. 2021;14:685-8. doi: 10.1016/j.jiph.2021.02.012. PubMed PMID: 33971576; PubMed Central PMCID: PMCPMC7936729.
آمار
تعداد مشاهده مقاله: 1,263
تعداد دریافت فایل اصل مقاله: 696


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب